IL201073A0 - Pyrrolopyrimidine derivatives as jak3 inhibitors - Google Patents

Pyrrolopyrimidine derivatives as jak3 inhibitors

Info

Publication number
IL201073A0
IL201073A0 IL201073A IL20107309A IL201073A0 IL 201073 A0 IL201073 A0 IL 201073A0 IL 201073 A IL201073 A IL 201073A IL 20107309 A IL20107309 A IL 20107309A IL 201073 A0 IL201073 A0 IL 201073A0
Authority
IL
Israel
Prior art keywords
jak3 inhibitors
pyrrolopyrimidine derivatives
pyrrolopyrimidine
derivatives
jak3
Prior art date
Application number
IL201073A
Other languages
English (en)
Original Assignee
Palau Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palau Pharma Sa filed Critical Palau Pharma Sa
Publication of IL201073A0 publication Critical patent/IL201073A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL201073A 2007-04-02 2009-09-21 Pyrrolopyrimidine derivatives as jak3 inhibitors IL201073A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07380088 2007-04-02
PCT/EP2008/053842 WO2008119792A1 (en) 2007-04-02 2008-03-31 Pyrrolopyrimidine derivatives as jak3 inhibitors

Publications (1)

Publication Number Publication Date
IL201073A0 true IL201073A0 (en) 2010-05-17

Family

ID=38475914

Family Applications (1)

Application Number Title Priority Date Filing Date
IL201073A IL201073A0 (en) 2007-04-02 2009-09-21 Pyrrolopyrimidine derivatives as jak3 inhibitors

Country Status (16)

Country Link
US (1) US20110160185A9 (show.php)
EP (1) EP2142550A1 (show.php)
JP (1) JP2010523522A (show.php)
KR (1) KR20100015353A (show.php)
CN (1) CN101679440A (show.php)
AR (1) AR065901A1 (show.php)
AU (1) AU2008234822A1 (show.php)
BR (1) BRPI0809992A2 (show.php)
CA (1) CA2682646A1 (show.php)
CL (1) CL2008000946A1 (show.php)
IL (1) IL201073A0 (show.php)
MX (1) MX2009010595A (show.php)
PE (1) PE20090996A1 (show.php)
RU (1) RU2009140319A (show.php)
TW (1) TW200904442A (show.php)
WO (1) WO2008119792A1 (show.php)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009026107A1 (en) 2007-08-17 2009-02-26 Portola Pharmaceuticals, Inc. Protein kinase inhibitors
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
NZ589315A (en) 2008-04-16 2012-11-30 Portola Pharm Inc 2,6-diamino-pyrimidin-5-yl-carboxamides as Spleen tryosine kinase (syk) or Janus kinase (JAK) inhibitors
AU2009238590A1 (en) 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
WO2010034740A1 (en) * 2008-09-23 2010-04-01 Palau Pharma, S.A. (r)-3-(n,n-dimethylamino)pyrrolidine derivatives
JP5431495B2 (ja) 2008-12-05 2014-03-05 エフ．ホフマン−ラ ロシュ アーゲー ピロロピラジニル尿素キナーゼ阻害薬
CA2764885C (en) * 2009-06-08 2018-05-15 Takeda Pharmaceutical Company Limited Dihydropyrrolonaphtyridinone compounds as inhibitors of jak
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
US8501735B2 (en) * 2009-10-29 2013-08-06 Palau Pharma, S.A. N-containing heteroaryl derivatives as JAK3 kinase inhibitors
EP2590981B1 (en) * 2010-07-09 2014-09-03 Leo Pharma A/S Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
RU2563644C2 (ru) * 2010-08-20 2015-09-20 Хатчисон Медифарма Лимитед Пирролопиримидиновые соединения и их применения
US20130225578A1 (en) * 2010-09-01 2013-08-29 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
US20130303533A1 (en) * 2010-09-01 2013-11-14 Ambit Biosciences Corporation Azolopyridine and azolopyrimidine compounds and methods of use thereof
CN104066431B (zh) 2011-11-23 2017-03-08 波托拉医药品公司 吡嗪激酶抑制剂
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
ES2827233T3 (es) * 2013-01-18 2021-05-20 Guangzhou Maxinovel Pharmaceuticals Co Ltd Compuesto heterocíclico de cinco y seis miembros, y método de preparación, composición farmacéutica y uso del mismo
KR101657616B1 (ko) * 2013-05-24 2016-09-19 주식회사유한양행 피리미딘 고리를 포함하는 바이사이클릭 유도체 및 그의 제조방법
US20170137426A1 (en) * 2014-03-28 2017-05-18 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as axl inhibitors
CN105315285B (zh) * 2014-07-25 2017-12-08 上海海雁医药科技有限公司 2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途
NO2721710T3 (show.php) * 2014-08-21 2018-03-31
CN105732636B (zh) * 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
EP3778605A3 (en) 2015-02-13 2021-03-10 Dana Farber Cancer Institute, Inc. Lrrk2 inhibitors and methods of making and using the same
CN104876934B (zh) * 2015-05-12 2017-08-11 山东大学 一种含氮杂环苯基哌啶类化合物及其制备方法与应用
EP3303348B1 (en) * 2015-05-28 2019-08-07 Theravance Biopharma R&D IP, LLC Naphthyridine compounds as jak kinase inhibitors
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
KR20250010141A (ko) 2015-10-16 2025-01-20 애브비 인코포레이티드 (3S,4R)-3-에틸-4-(3H-이미다조[1,2-a]피롤로[2,3-e]-피라진-8-일)-N-(2,2,2-트리플루오로에틸)피롤리딘-1-카복스아미드및 이의 고체상 형태의 제조 방법
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
CN111788204B (zh) 2018-02-26 2023-05-05 吉利德科学公司 作为hbv复制抑制剂的取代吡咯嗪化合物
CN110526915B (zh) * 2018-05-25 2022-02-01 首药控股(北京)股份有限公司 一种间变性淋巴瘤激酶抑制剂的制备方法
CN113272306A (zh) 2018-11-05 2021-08-17 爱维斯塔制药解决方案有限公司 化学化合物
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
EP3955920A1 (en) 2019-04-16 2022-02-23 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
EP3971190A4 (en) * 2019-05-17 2023-06-14 Voronoi Inc. HETEROCYCLICALLY CONDENSED PYRIMIDIDE DERIVATE AND USE THEREOF
CN110183471B (zh) * 2019-05-21 2022-02-15 江苏大学 一种哌嗪类衍生物及制备方法及应用
CN110317176A (zh) * 2019-07-04 2019-10-11 沈阳药科大学 2-氨基嘧啶类化合物及其用途
CN116528869A (zh) * 2020-11-27 2023-08-01 安锐生物医药科技(广州)有限公司 氨基杂芳基激酶抑制剂
WO2022117012A1 (zh) * 2020-12-02 2022-06-09 百极弘烨（广东）医药科技有限公司 螺环jak抑制剂、含其的药物组合物及其应用
WO2022216097A1 (ko) * 2021-04-08 2022-10-13 주식회사 스탠다임 신규한 lrrk2 억제제
EP4526469A1 (en) 2022-05-16 2025-03-26 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation
CA3260763A1 (en) * 2022-06-29 2024-01-04 Alcon Inc. AZETIDINYL PYRIMIDINES AND THEIR USES AS JAK INHIBITORS
CN118005609B (zh) * 2022-11-09 2025-06-17 沈阳药科大学 2-氨基嘧啶类化合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100415791B1 (ko) * 1998-06-19 2004-01-24 화이자 프로덕츠 인코포레이티드 피롤로[2,3-디]피리미딘 화합물
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
ZA200707342B (en) * 2005-02-03 2009-03-25 Vertex Pharma Pyrrolopyrimidines useful as inhibitors of protein kinase
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
WO2008119792A1 (en) 2008-10-09
KR20100015353A (ko) 2010-02-12
BRPI0809992A2 (pt) 2014-10-14
JP2010523522A (ja) 2010-07-15
AR065901A1 (es) 2009-07-08
TW200904442A (en) 2009-02-01
RU2009140319A (ru) 2011-05-10
EP2142550A1 (en) 2010-01-13
US20110160185A9 (en) 2011-06-30
US20100113420A1 (en) 2010-05-06
CL2008000946A1 (es) 2008-10-10
MX2009010595A (es) 2009-10-22
CA2682646A1 (en) 2008-10-09
CN101679440A (zh) 2010-03-24
PE20090996A1 (es) 2009-07-15
AU2008234822A1 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
IL201073A0 (en) Pyrrolopyrimidine derivatives as jak3 inhibitors
HUS1700051I1 (hu) Pirrolopiridin vegyületek, mint CDK inhibitorok
IL190077A0 (en) Pyrrolopyrimidine derivatives as syk inhibitors
IL210990A0 (en) Piperidine derivatives as jak3 inhibitors
ZA200807447B (en) Thieno-Pyridine derivatives as MEK inhibitors
IL194755A0 (en) Pyrimidine derivatives as pi3k inhibitors
IL200617A0 (en) Substituted pyrimidodiazepines useful as plk1 inhibitors
IL198675A0 (en) Novel aminopyrimidine derivatives as plk1 inhibitors
IL212687A0 (en) Pyrazine compounds as phosphodiesterase 10 inhibitors
ZA201005166B (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
IL184674A0 (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
IL195010A0 (en) Bicyclic derivatives as cetp inhibitors
IL200047A0 (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
EP2046333A4 (en) THIOZOLIDINEDIONE DERIVATIVES AS INHIBITORS OF P13-KINASE
ZA201102123B (en) Substituted triazolo-pyridazine derivatives
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
ZA200803030B (en) Pyrrolopyrimidine derivatives as Syk inhibitors
ZA200808598B (en) Pyrrolopyrimidine derivatives used as HSP90 inhibitors
ZA200905235B (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
ZA200903127B (en) Novel aminopyrimidine derivatives as PLK1 inhibitors
ZA201104380B (en) Pyrazine compounds as phosphodiesterase 10 inhibitors
GB0617789D0 (en) Pyrrolopyrimidine compounds
ZA200706212B (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors